In two studies that reported details on diabetes treatment the percentage of patients requiring insulin therapy ranged from 17.6 to 24% (37, 41)
On January 7, 2026, a threat actor breached OpenLoops systems and claimed to have exfiltrated records from approximately 1.6 million patients, including names, contact information, dates of birth and medical information
The team reported a comparative picture with men as well
Semaglutide is an appetite suppressant that is primarily used to treat type 2 diabetes and obesity, as indicated, and approved by the Food and Drug Administration (FDA)
A classification of diabetes management drugs commonly known as GLP-1 agonists have specifically contributed to a spike in health insurance spending from 2022 to 2023, the costs for GLP-1 drugs paid on behalf of our members grew by more than $350 million
Common Misconceptions About GLP-1 Medications It is just an appetite suppressant. Not really